Kura Oncology (NASDAQ: KURA) reported Q3 EPS of ($0.85), $0.10 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $20.75 million versus the consensus estimate of $20.66 million.

For earnings history and earnings-related data on Kura Oncology (KURA) click here.